- Home
- FANG vs TAK Comparison
FANG vs TAK Comparison
Compare FANG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FANG
- TAK
- Stock Information
- Founded
- FANG 2007
- TAK 1781
- Country
- FANG United States
- TAK Japan
- Employees
- FANG N/A
- TAK N/A
- Industry
- FANG Oil & Gas Production
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- FANG Energy
- TAK Health Care
- Exchange
- FANG Nasdaq
- TAK Nasdaq
- Market Cap
- FANG 40.3B
- TAK 43.3B
- IPO Year
- FANG 2012
- TAK N/A
- Fundamental
- Price
- FANG $147.21
- TAK $14.30
- Analyst Decision
- FANG Strong Buy
- TAK
- Analyst Count
- FANG 19
- TAK 0
- Target Price
- FANG $186.28
- TAK N/A
- AVG Volume (30 Days)
- FANG 1.7M
- TAK 2.9M
- Earning Date
- FANG 11-03-2025
- TAK 10-30-2025
- Dividend Yield
- FANG 2.77%
- TAK 1.94%
- EPS Growth
- FANG N/A
- TAK N/A
- EPS
- FANG 14.37
- TAK 0.14
- Revenue
- FANG $14,626,000,000.00
- TAK $29,846,840,032.00
- Revenue This Year
- FANG $40.11
- TAK $0.01
- Revenue Next Year
- FANG N/A
- TAK $0.49
- P/E Ratio
- FANG $10.05
- TAK $102.02
- Revenue Growth
- FANG 59.73
- TAK N/A
- 52 Week Low
- FANG $114.00
- TAK $12.80
- 52 Week High
- FANG $186.07
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- FANG 58.11
- TAK 59.90
- Support Level
- FANG $137.03
- TAK $13.50
- Resistance Level
- FANG $149.97
- TAK $13.68
- Average True Range (ATR)
- FANG 3.93
- TAK 0.17
- MACD
- FANG 0.62
- TAK 0.11
- Stochastic Oscillator
- FANG 86.40
- TAK 93.31
About FANG Diamondback Energy Inc.
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2024, the company reported net proven reserves of 3.6 billion barrels of oil equivalent. Net production averaged about 598,000 barrels per day in 2024, at a ratio of 56% oil, 23% natural gas liquids, and 21% natural gas.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.